Compass Therapeutics shares have experienced typical fluctuations characteristic of clinical-stage biotech equities, responding dynamically to periodic updates on clinical trial enrollments, upcoming medical conference presentations, quarterly financial burn reports, and broader market shifts in healthcare sector risk appetite.